Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Praneeth Reddy Sudalagunta, PhD, applied research scientist, Moffitt Cancer Center, Tampa, Florida, discusses the differential effects of bridging therapy on the immune microenvironment as well as outcomes with…
Joe Minniti, the Executive Director of the Cancer Foundation for Personal Appearance and Larry Cohen, Executive Vice President of the NIA Group, talk about the NIA group’s support…
Michael Banks, MD, provides an overview of diffuse brainstem gliomas. This video is dedicated to the memory of Max Scotti. About Making Headway Foundation Making Headway® is a…
NEW YORK (Reuters Health) – Initiating second-line chemotherapy for ovarian cancer recurrence based on an increase in the tumor marker CA125 alone does not improve overall survival compared…
NEW YORK (Reuters Health) – Most patients with synchronous metastatic (stage IV) colorectal cancer can forgo surgery to remove the primary tumor, at least initially, opting instead for…
NEW YORK (Reuters Health) – Rituximab (Rituxan) has been implicated in 57 cases of progressive multifocal leukoencephalopathy (PML) in HIV-negative patients diagnosed with hematologic malignancies or autoimmune diseases,…
NEW YORK (Reuters Health) – Combining hepatic artery infusion of floxuridine/dexamethasone with systemic oxaliplatin and irinotecan can make liver metastases from colorectal cancer resectable in about half of…
On April 22nd, 2009, people from around the globe gathered at US Cellular Field in Chicago to announce the Learning Living & Loving campaign. This call to action…
NEW YORK (Reuters Health) – Advanced prostate cancer appears to be of a more aggressive type when it occurs in young men, leading to dramatically higher cancer-specific mortality…
NEW YORK (Reuters Health) – In cancer patients accidentally overexposed with 5-fluorouracil (5-FU) chemotherapy, the investigational drug vistonuridine (Wellstat Therapeutics Corp) may be lifesaving, according to research to…
Kim Hunter-Schaedle, PhD, Chief Scientific Officer of the Children’s Tumor Foundation, discusses Neurofibromatosis, a complex disorder that affects 1 in 3000 children, making it more common than better…
